Background: A high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health.
T
he Centers for Disease Control and Prevention estimates that 6500 women with HIV give birth annually in the United States (1) . A high maternal plasma HIV-1 RNA level (viral load [VL] ) is a major risk factor for mother-to-child transmission (MTCT) (2) (3) (4) (5) (6) . Use of highly active antiretroviral therapy (HAART) to suppress viral replication has become a mainstay in the management of HIV in pregnant women in developed nations, decreasing MTCT rates at delivery to 1% to 2% (7) (8) (9) (10) .
Despite the widespread use of HAART in the United States, some women still have detectable VL at delivery; every infant born with HIV is a missed prevention opportunity (11) . Viral suppression reduces MTCT risk and confers important benefits to maternal health both during and after pregnancy (12, 13) . Factors associated with detectable VL (>400 copies/mL) at delivery include advanced HIV disease, late initiation of HAART, and inability to adhere to treatment (14 -16) .
Results are mixed about the role of different antiretroviral (ARV) regimens. Although 1 previous report showed varying virologic response according to regimen type (17) , a large observational study found no difference in response by ARV regimen (18) . A randomized trial of women with a CD4 + count of 0.2 × 10 9 cells/L or greater in Botswana comparing the effect of a nucleoside reverse-transcriptase inhibitor (NRTI)-based regimen with a boosted protease inhibitor (PI)-based regimen on VL at delivery saw high rates of virologic suppression at delivery and no difference between regimens (19) . This study aimed to identify risk factors associated with detectable VL at delivery among women who initiated HAART for the first time during pregnancy.
METHODS

Design
The International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group Protocol 1025 study is a multicenter observational study in the United States (including Puerto Rico) designed to assess maternal and infant safety, effectiveness of interventions prescribed for the prevention of MTCT, and women's health (the Appendix, available at www.annals.org, lists the study team and sites). Enrollment began in October 2002. Women with HIV aged 13 years or older could enroll between 8 weeks of gestation and 14 days after delivery and again for subsequent pregnancies. Additional details of Protocol 1025 study procedures have been published (20) . Institutional review boards approved the protocol at all 67 clinical sites, and written
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informed consent was obtained from the patients enrolled.
Eligibility
The study population eligible for this analysis included women who enrolled in Protocol 1025 for the first time before delivery, had an estimated date of confinement on or before 31 December 2011, had available VL data between 14 days before and 7 days after delivery, were ARV-naive before pregnancy, and initiated HAART during the index pregnancy. Highly active antiretroviral therapy was defined as a regimen of 3 or more ARV drugs, including 2 NRTIs combined with either a nonnucleoside reverse transcriptase inhibitor (NNRTI), a nonboosted PI (without ritonavir), a boosted PI (with ritonavir), or a third NRTI.
Variable Selection
Selection of analysis variables was driven by clinical hypotheses using covariates known at baseline and others shown to be relevant in previous studies. The outcome of interest was detectable VL at delivery, defined as a VL greater than 400 copies/mL, the standard assay limit of quantification before 2008. Baseline characteristics were assessed at the time HAART was initiated in pregnancy, and characteristics of ARV management and adherence were assessed through the remainder of the pregnancy.
Baseline characteristics included maternal age, race or ethnicity, and highest education level attained; obstetric information, including parity and timing of the first prenatal visit; and HIV and treatment characteristics, including the trimester of HAART initiation, the first HAART regimen used in pregnancy, the timing of HIV diagnosis, the Centers for Disease Control and Prevention clinical classification (21), and the pretreatment CD4 + cell count and VL measures. We used ARV regimen information collected via chart abstraction to calculate the number of and reasons for regimen changes and medication interruptions that occurred during pregnancy. We did not consider a formulation change or intravenous zidovudine at the time of delivery to be a regimen change. A medication interruption was defined as an interval greater than 1 day between a regimen stop date and subsequent regimen start date. Adherence to HAART was self-reported at each study visit using an interviewer-administered questionnaire, which included questions about the current regimen, the number of doses missed for each ARV of the regimen over the 3 days before the study visit, and a multiple-choice question about the last time a dose was missed (22) . We selected the interviews completed closest to delivery for this analysis.
Statistical Analysis
We summarized and compared the distribution of the covariates of interest by trimester of HAART initiation and compared the proportion with detectable VL at delivery across levels of each covariate using chisquare tests. We explored associations between covariates and VL at delivery using logistic regression models. Many covariates were closely related, and we selected 1 covariate from each group of related covariates (maternal age and parity; regimen composition and calendar year; and timing of the first prenatal visit, HIV diagnosis, and HAART initiation) for inclusion in multivariable logistic regression models.
We used multiple imputation to account for lack of availability of pretreatment VL data for 29% of women because of Protocol 1025's observational study design. Thirty imputations were used, and the imputation model included all covariates from our final model, plus VL at delivery. Data were imputed using PROC MI under the assumption that missing pretreatment VL was missing at random, and final estimates were found using PROC MIANALYZE. Predicted probabilities, evaluated at the mean value of all other covariates in the model, were estimated from this model and reported as adjusted probabilities. We explored results by pretreatment VL and timing of HAART initiation because we expected both factors to be strongly related to VL at delivery and to each other. Because of concerns that self-reported adherence data were not missing randomly, we did not include adherence in our multivariable models and instead explored the association between adherence and VL at delivery more descriptively in women who had complete adherence data available. We considered a 2-sided P value less than 0.05 statistically significant and conducted all analyses with SAS, version 9.2 (SAS Institute).
Role of the Funding Source
This study was funded by the U.S. Department of Health and Human Services. The funding source did not participate in the study design, data collection, analysis and interpretation of the data, or the decision to submit the manuscript for publication.
EDITORS' NOTES Context
Despite widespread use of highly active antiretroviral therapy (HAART) in the United States, some women still have detectable viral load at delivery, increasing risk for vertical transmission.
Contribution
Among women with HIV who initiated HAART during pregnancy, the 13.1% with detectable virus at delivery were more likely than those with undetectable virus to be non-Hispanic black, have a low educational level, have initiated HAART and/or prenatal care in the third trimester, and have poor HAART adherence.
Implication
Socially disadvantaged pregnant women with HIV, who are at greater risk for having detectable viral load at delivery, may benefit from interventions to promote early prenatal care, early HAART initiation, and medication adherence.
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RESULTS
Of the 2294 women enrolled in Protocol 1025 with an estimated date of confinement between October 2002 and December 2011, 1013 (44.2%) had not used ARVs before pregnancy. Of these women, 15 who did not receive HAART during pregnancy, 186 who enrolled at or after delivery, and 141 with no delivery VL data were excluded, leaving 671 women eligible for this analysis. Women without delivery VL data were more likely to be black. The median number of patients per site was 6.5 (first to third quartile, 4 to 14 patients [range, 1 to 63 patients]). Table 1 describes baseline sociodemographic, HIV disease, and treatment characteristics of the cohort by the timing of HAART initiation. Of women with available data, most (88.1%) had a VL greater than 400 copies/mL before HAART initiation, 35.0% had a VL between 10 000 and 99 999 copies/mL, and 7.3% had a VL of 100 000 copies/mL or greater. Approximately one half (52.6%) of women received a boosted PIbased regimen (79.3% received lopinavir or ritonavir, and most of the remainder received atazanavir or ritonavir), 23.7% received an unboosted PI-based regimen (95.0% containing nelfinavir), 7.3% received an NNRTI-based regimen (85.7% containing nevirapine and 14.3% containing efavirenz), and 16.4% received a triple NRTI-based regimen (most with abacavir) as their initial regimen during pregnancy. Women who initiated HAART in the third trimester were significantly more likely to be black, have started prenatal care and enrolled in Protocol 1025 later, been diagnosed with HIV more recently, and have a lower pretreatment VL than those initiating HAART earlier in pregnancy. Multiparous women were older than nulliparous women (median age, 28.8 vs. 23.5 years; P < 0.001), and those with a more recent estimated date of confinement (2008 to 2011) were more likely to have initiated use of boosted PI regimens than in previous years (>70.9% vs. <37.7%; P < 0.001). Table 2 summarizes treatment management and adherence during pregnancy. Thirty-nine (5.8%) women had at least 1 treatment interruption during pregnancy. The median interruption duration was 12 days (first to third quartile, 5 to 39 days). The most common reasons reported for treatment interruptions were toxicity, teratogenicity, or obstetric complications (59.0%) and nonadherence (28.2%). Six women withdrew completely (3 due to nonadherence and 3 due to toxicity). In addition, 137 (20.4%) women changed regimens at least once during pregnancy; 96 received 2 regimens, 33 received 3 regimens, and 8 received 4 regimens. Women who received NNRTI regimens first were most likely to change regimens, and women who received triple NRTI regimens first were least likely to change regimens relative to the other regimen types. The reasons reported for medication changes included toxicity, teratogenicity, or obstetric complication (40.9%); clinician request (30.7%); nonadherence (5.8%); patient request (3.6%); and virologic failure or drug resistance (3.6%). Of the 541 women (80.6%) with ARV adherence data available, 22.0% and 20.2% reported nonadherence within the preceding 2 weeks or 3 days, respectively, of the last adherence assessment before delivery. The percentage of women without adherence data seemed to differ according to ethnicity (higher among Hispanic and black women relative to white nonHispanic women), site, calendar year, type of regimen, and overall duration of HAART during pregnancy. Table 3 summarizes pregnancy outcomes. Median gestational age at delivery was 38.3 weeks, and 85.7% of women delivered at 37 weeks of gestation or later. Of women with detectable VL at delivery, 64.8% delivered by cesarean section and 35.2% delivered vaginally. In contrast, of women with a VL less than 400 copies/mL at delivery a significantly greater proportion (50.8%) delivered vaginally. We did not see a significant difference in gestational age at delivery by VL. There was 1 confirmed MTCT (0.2%); the mother was diagnosed with HIV during the pregnancy and received HAART for 12 weeks before delivery. She had detectable VL (between 1000 and 9999 copies/mL) both before treatment and at the time of delivery. At her visit closest to delivery, she reported missing ARVs during the previous 2 weeks.
Eighty-eight women (13.1%) had detectable VL at delivery. Of these women, 59 (67.0%) had a VL of 1000 copies/mL or greater, 13 (14.8%) had a VL between 10 000 and 99 999 copies/mL, and 3 (3.4%) had a VL of 100 000 copies/mL or greater. In univariate comparisons (Table 4 ), race or ethnicity, level of education, parity, timing of the first prenatal visit, and timing of HAART initiation were associated with detectable VL at delivery. Data in women with pretreatment VL suggested an association between greater proportions with detectable VL at delivery (≥10 000 copies/mL) and greater VL before treatment (15.8% vs. 10.2%; P = 0.065). There was some evidence that the proportion with detectable VL at delivery was marginally greater with nonboosted PI-containing regimens compared with boosted PI-containing regimens (17.0% vs. 11.6%; P = 0.140). In the multivariable modeling after multiple imputation of missing pretreatment VL (Table  4) , the significant predictors in univariate analyses continued to be associated with VL at delivery. In addition, pretreatment VL was significantly associated with VL at delivery. When the multivariable modeling was restricted to the subset of women with complete pretreatment VL, results remained consistent.
In univariate analyses of treatment management characteristics, women with at least 1 treatment interruption were more likely to have detectable VL at delivery than those with no interruption (28.2% vs. 12.2%; P = 0.004), but regimen changes were not significantly associated with detectable VL at delivery. When treatment interruption was added to the multivariable model, it remained statistically significant (adjusted probability, 24.3% [95% CI, 13.0% to 40 .8%] with interruptions vs. 9.0% [CI, 6.7% to 11.9%] with no interruptions; P = 0.002), and the P values and adjusted probabilities for the pretreatment variables did not change substantially. In the subset of women with complete ad-
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herence data (n = 541), the proportion with detectable VL at delivery was greatest among women who reported nonadherence in the previous 2 weeks (19.3%) versus earlier (12.3%) or never (9.6%) (P = 0.039).
There was some variation in the adjusted probabilities of detectable VL at delivery by pretreatment VL and the trimester of HAART initiation, although estimates were imprecise. Among women with pretreat- 
DISCUSSION
In this large U.S.-based cohort of HAART-naive women with HIV, 13.1% had detectable VL at delivery. Although this percentage of women with persistent viremia at delivery is concerning, this estimate is lower than the 24% of HAART-naive women with detectable VL at delivery seen in an earlier U.S. cohort (18) . The timing of HAART initiation and consistent use during pregnancy were associated with VL at delivery. Among women who initiated HAART in the third trimester, nearly one quarter (23.9%) had detectable VL at delivery.
A recent retrospective study from the United Kingdom recommended that women with VL greater than 10 000 copies/mL should begin HAART by 20.4 weeks, whereas those with VL greater than 100 000 copies/mL should start HAART without delay (23) . In that study, women with VL less than 10 000 copies/mL could potentially begin HAART by 26.3 weeks to achieve an undetectable VL by delivery, but this should be balanced against the possible increased risk for in utero transmission with a delayed start or the risk for transmission should a premature delivery occur. 
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Our data suggest that the timing of HAART initiation may be more strongly associated with detectable VL among women who have high VL before treatment (≥10 000 copies/mL) than among those who have lower VL before treatment (<10 000 copies/mL). The timing of HAART initiation during pregnancy deserves special attention because vaginal deliveries in women with HIV are recognized to be safer for women and equally safe as cesarean sections for newborns if VL is nondetectable at delivery (24) . For HAART-naive women, the updated U.S. Department of Health and Human Services perinatal guidelines from July 2012 Factors Associated With Lack of Viral Suppression ORIGINAL RESEARCH recommend starting the regimen in the first trimester or delaying until 12 weeks of gestation depending on CD4 + cell count; HIV RNA levels; and maternal conditions, such as nausea and vomiting. Earlier initiation of a combination regimen may be more effective in reducing transmission, but benefits must be weighed against potential fetal effects of first-trimester drug exposure (24) .
One important consideration about when to start HAART extends beyond the benefits for maternal health and decreasing neonatal transmission rates. There is emerging literature focused on the effects of maternal viremia on long-term outcomes after delivery in HIV-exposed, uninfected (HEU) children. Research from South Africa shows that both children with HIV and HEU children younger than 1 year were at increased risk for unsuccessful treatment of severe pneumonia (25) . More recent findings corroborate the greater infectious illness among this population (26) . Poor outcomes in HEU infants may relate to the altered CD4 + immunity during the first year of life (27) . Infants born to immunosuppressed mothers have increased exposure to pathogens (28) . Subsequent research has shown that HEU infants present various immunologic abnormalities, including impaired immune response to vaccines (29) as compared with unexposed neonates; however, whether this is related to maternal HIV infection or to use of HAART remains unclear (30) .
Missing data precluded us from incorporating adherence data into a multivariable analysis, but it seems that women who reported suboptimal adherence had higher rates of detectable VL at delivery than women who reported optimal adherence. These findings are supported by other studies that showed the importance of early HAART initiation (31) , as well as medication adherence both within (32) and outside the context of pregnancy (33) , and suggest that HAART can only achieve its optimal efficacy in prevention of MTCT, illness, and death if persons with HIV initiate treatment promptly and adhere to their medications (34 -36) . Our findings provide further evidence of the importance of early HAART initiation (37) and support of medication adherence throughout pregnancy.
Women with greater VL before treatment and those receiving less potent regimens containing unboosted PIs had greater probability of having detectable VL at delivery. The AIDS 2012 International Antiviral Society-USA treatment guidelines stressed that initial therapy for all adults, including pregnant women, should optimize potency of the regimen and be based on a combination of 2 NRTIs and a third agent, generally consisting of an NNRTI, a ritonavir-boosted PI, an integrase strand transfer inhibitor, or, rarely, an agent that blocks the C-C chemokine receptor 5 (38) . Unboosted PIs are not considered first-line therapy at this time, and our findings reflect that a regimen containing a PI without ritonavir boosting is suboptimal and this was generally not prescribed after 2007.
We also identified several sociodemographic factors associated with detectable VL at delivery: black non-Hispanic ethnicity and educational attainment less than a high school diploma. Previous studies have identified race-associated disparities in maternal HIV disease outcomes, including high VL at delivery (16, 39 -41) . It is possible that experiences of race-based discrimination or lack of trust in the medical care system may pose barriers to engagement in care, which, in turn, could be associated with unsuppressed VL. For example, Thorburn and Bogart (42) found that black women frequently reported race-based discrimination when seeking family-planning and contraceptive services. In a different study of a random cross-sectional sample of black persons, approximately 60% endorsed HIV conspiracy beliefs (43) . There may also be racial variations in drug pharmacokinetics during pregnancy and risk for virologic failure (44) or ethnic differences in the sites where patients receive care and resources devoted to promoting adherence. Education is an important social determinant of health. As a marker of socioeconomic status, lower levels of education have been linked to suboptimal engagement in care, nonadherence to ARV therapy, and lower rates of survival in persons with HIV (45, 46) . Although the mechanisms linking lower educational attainment to detectable VL at delivery remain unclear, it may reflect lower levels of health literacy or be a marker of overall poverty. Lower health literacy and greater poverty-related stress have been linked to medication nonadherence and other negative health outcomes (47) (48) (49) .
A limitation of this observational study is that women could enroll at any time during their pregnancy. Thus, data on some covariates are incomplete, and study entry did not correspond with entry into prenatal care or initiation of treatment. Women who enrolled in the study during their third trimester were more likely to have missing pretreatment VL and CD4 + data. In addition, correlations among maternal age, parity, calendar year, treatment regimen, timing of HAART initiation, first prenatal visit, and HIV diagnosis prohibited drawing conclusions about the independent effects of these factors on detectable VL at delivery. In addition, a large amount of missing adherence data and reliance on self-report for adherence prevented the inclusion of adherence in multivariable analyses, and results should be interpreted with caution. Despite this, our findings are consistent with previous studies related to medication adherence in a U.S.-based population of pregnant women with HIV (22) .
Generalizability is uncertain because this study occurred at AIDS clinical trial sites and may not reflect patients in the community. These sites are geographically and demographically diverse, but small numbers of women at each site and lack of sociodemographic variation within sites inhibited our ability to account for site effects. Some sites enrolled mostly or all black nonHispanic women, whereas other sites enrolled mostly or all Hispanic women. Therefore, the association that we found between ethnicity and VL may have been due to site factors rather than ethnicity. Finally, we did not have resistance data for most women. Despite these limitations, to our knowledge, our study is one of the largest U.S.-based analyses evaluating the association
between ARV therapy and virologic suppression at delivery in the current era of HAART.
Our results suggest that women who initiate HAART in the third trimester have greater VL before treatment or have suboptimal ARV adherence are at increased risk for having detectable VL at delivery. Optimal care for HAART-naive pregnant women with HIV should focus on initiation of HAART according to pretreatment VL and before the third trimester. Additional interventions should focus on early prenatal care, early HIV testing, and measures to support adherence to treatment throughout pregnancy to promote both maternal and infant health.
